NEWRON PHARMACEUT. EO-20 (F:NP5) — Stock Price
NEWRON PHARMACEUT. EO-20 (F:NP5) is currently trading at €12.90 EUR, up 1.18% today. Over the past 52 weeks, shares have ranged between €7.25 and €33.05. This page tracks NEWRON PHARMACEUT. EO-20's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see NP5 market cap.
NEWRON PHARMACEUT. EO-20 (NP5) Stock Price Chart — Daily History & Trading Volume
The chart below tracks NEWRON PHARMACEUT. EO-20's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
NEWRON PHARMACEUT. EO-20 Income Statement — Revenue, Profit & Earnings by Year
NEWRON PHARMACEUT. EO-20's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €19.13 Million | €51.39 Million | €9.06 Million | €6.09 Million | €5.76 Million |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | €15.12 Million | €13.64 Million | €13.15 Million | €12.01 Million | €10.72 Million |
| SG&A | €4.85 Million | €7.50 Million | €4.06 Million | €3.62 Million | €3.53 Million |
| Total Operating Expenses | €23.82 Million | €25.22 Million | €20.69 Million | €19.40 Million | €18.12 Million |
| Operating Income | €-4.70 Million | €26.17 Million | €-11.63 Million | €-13.30 Million | €-12.36 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €4.40 Million | €4.35 Million | €4.17 Million | €3.95 Million | €2.92 Million |
| Income Before Tax | €-12.35 Million | €21.39 Million | €-16.20 Million | €-17.47 Million | €-14.88 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-13.24 Million | €15.84 Million | €-16.22 Million | €-17.49 Million | €-14.90 Million |
NEWRON PHARMACEUT. EO-20 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes NEWRON PHARMACEUT. EO-20's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €40.05 Million | €63.91 Million | €25.87 Million | €37.20 Million | €50.49 Million |
| Total Current Assets | €38.08 Million | €61.10 Million | €19.65 Million | €28.49 Million | €39.43 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €16.69 Million | €2.89 Million | €6.26 Million | €9.35 Million | €9.57 Million |
| Net Receivables | €2.54 Million | €42.12 Million | €2.02 Million | €1.94 Million | €1.31 Million |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €51.19 Million | €62.45 Million | €55.77 Million | €51.23 Million | €47.38 Million |
| Total Current Liabilities | €50.13 Million | €23.51 Million | €28.93 Million | €5.04 Million | €3.65 Million |
| Long-term Debt | €0.00 | €36.24 Million | €25.75 Million | €45.16 Million | €42.54 Million |
| Net Debt | €25.28 Million | €42.72 Million | €41.69 Million | €31.74 Million | €17.52 Million |
| Total Stockholder Equity | €-11.13 Million | €1.46 Million | €-29.91 Million | €-14.03 Million | €3.11 Million |
| Retained Earnings | €-18.27 Million | €10.69 Million | €-21.40 Million | €-22.80 Million | €-20.12 Million |
NEWRON PHARMACEUT. EO-20 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how NEWRON PHARMACEUT. EO-20 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €32.35 Million | €-17.61 Million | €-10.14 Million | €-11.09 Million | €-11.45 Million |
| Capital Expenditures | €48.00K | €13.00K | €11.00K | €18.00K | €20.00K |
| Free Cash Flow | €32.30 Million | €-17.63 Million | €-10.15 Million | €-11.11 Million | €-11.46 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €212.00K | €256.00K | €197.00K | €480.00K | €762.00K |
| Depreciation | €172.00K | €192.00K | €201.00K | €202.00K | €209.00K |
| Change in Cash | €5.25 Million | €595.00K | €-7.09 Million | €-11.60 Million | €11.81 Million |
NEWRON PHARMACEUT. EO-20 Earnings History — EPS Actual vs. Analyst Estimates
Track NEWRON PHARMACEUT. EO-20's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 14, 2025 | — | — | — |